Endovascular Engineering
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $150.0Mattributed |
|---|---|
| Latest round | series-c, $80.0M, 2026-04-01attributed |
| Founded | 2018 |
| Headquarters | Menlo Park CA |
| Industry | healthtech |
| Stage | series-b+ |
| Website | e2.bio |
Endovascular Engineering develops the Helo Thrombectomy Platform, a system for non-surgically removing blood clots from pulmonary arteries and veins. It serves clinicians treating pulmonary embolism and venous thromboembolism. Its differentiator is a patented dual-action design combining mechanical clot disruption with aspiration.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-04-01 | series-c | $80.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series C, $80.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $150.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | e2.bio, read 2026-05-02 |
| Description | self-reported | e2.bio, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.